Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00518661 · ClinicalTrials.gov registry record
Risk Factors for Quinolone Resistance Among ESBL Producing Klebsiella Species
A clinical trial, sponsored by University of Pittsburgh.
- Completed
- Registry status
- 500
- Enrollment target
NCT00518661: Completed study, sponsored by University of Pittsburgh.
NCT00518661 is a clinical trial that has completed, run by University of Pittsburgh. The registered enrollment target is 500 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00518661 has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- 500 participants
- Enrollment target
Study Summary
This is a retrospective chart review. This proposed study aims to document the risk factors for quinolone resistance in bloodstream isolates of Klebsiella species. Additionally, the adequacy of empiric antibiotic therapy for Klebsiella bloodstream infections will be assessed.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2007-08 |
| Est. Completion | 2017-12 |
What the finished NCT00518661 record still lists
NCT00518661 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00518661 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00518661 about?
NCT00518661 is a clinical study titled "Risk Factors for Quinolone Resistance Among ESBL Producing Klebsiella Species". This is a retrospective chart review. This proposed study aims to document the risk factors for quinolone resistance in bloodstream isolates of Klebsiella species. Additionally, the adequacy of empiric antibiotic therapy for Klebsiella bloodstream infections will be assessed.
What is the current status of trial NCT00518661?
This trial is currently completed. The enrollment target is 500 participants. The study started on 2007-08. Estimated completion is 2017-12.
Who is sponsoring clinical trial NCT00518661?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia